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Abstract
Purpose: Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate
cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617,
referred to as [111In]PSMA-617) as a γ-emitting tracer for intraoperative γ-probe application for resected tissue
samples in PCa patients. Forty-eight hours prior to LA, [111In]PSMA-617 was administered intravenously in 23
patients with suspected LNM on PSMA-PET/CT (n = 21 with biochemical relapse, n = 2 at primary therapy).
Resected tissue samples (LN, LNM and fibrofatty tissue) were measured ex situ by a γ-probe expressed as counts
per second (CPSnorm). [
111In]PSMA-617 tissue sample uptake was measured by a germanium detector for verification
and calculated as %IAlbm (percent injected activity per kilogram lean body mass at time of surgery). Based on a
clinical requirement for a specificity > 95%, thresholds for both ex situ measurements were chosen accordingly.
Correlation of the results from PET/CT, γ-probe and germanium detector with histopathology was done.
Results: Eight hundred sixty-four LNs (197 LNM) were removed from 275 subregions in 23 patients, on average 8.6
± 14.9 LNM per patient. One hundred four of 275 tissue samples showed cancer. Median γ-probe and germanium
detector results were significantly different between tumour-affected (33.5 CPSnorm, 0.71 %IAlbm) and tumour-free
subregions (3.0 CPSnorm, 0.03 %IAlbm) (each p value < 0.0001). For the chosen γ-probe cut-off (CPSnorm > 23) and
germanium detector cut-off (%IAlbm > 0.27), 64 and 74 true-positive and 158 true-negative samples for both
measurements were identified. Thirty-nine and 30 false-negative and 6 and 5 false-positive tissue samples were
identified by γ-probe and germanium detector measurements.
Conclusion: [111In]PSMA-617 application for LA is feasible in terms of an intraoperative real-time measurement with
a γ-probe for detection of tumour-affected tissue samples. γ-probe results can be confirmed by precise germanium
detector measurements and were significantly different between tumour-affected and tumour-free samples.
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Background
Prostate cancer (PCa) is the most commonly diagnosed
cancer in men. It can be cured by surgical removal of
the prostate (radical prostatectomy) with pelvic lymph-
adenectomy (LA) or by radiotherapy (RT) [1–4]. The
risk of metastases is mainly determined by the Gleason
score, the level of PSA (prostate-specific antigen) and
tumour extension (TNM status) [3, 4]. Pelvic and retro-
peritoneal lymph nodes (LN) are the first sites for metas-
tases [2–4]. LN metastases (LNM), if assumed at
primary therapy, should be removed at radical prostatec-
tomy with LA in order to improve oncological outcome
and enable correct staging [2–5]. An accurate preopera-
tive detection of LNM by, e.g., positron emission tomog-
raphy/computed tomography (PET/CT) is a prerequisite
for successful surgery [6, 7].
Despite primary therapy, about 15–30% of the
patients will develop a biochemical recurrence with ele-
vated PSA level and clinical recurrence (metastases)
possible at different sites (e.g. local relapse, LNM,
bone). A systemic therapy such as ADT or chemother-
apy is still the standard treatment in the stage of meta-
static prostate cancer [3]. Regretfully, during systemic
therapy, PCa will inevitably develop a resistance to an-
drogen deprivation or chemotherapy, which will end up
in tumour progression again.
PET/CT targeting prostate-specific membrane antigen
(PSMA) has demonstrated an excellent ability to detect
LNM prior to surgery [6, 8–11] and is widely used as a
tool for staging before primary therapy restaging of PCa
patients in the setting of biochemical relapse [8–10, 12].
The most widely studied is 68Ga labelled to the small
molecular inhibitor PSMA-11 via the HBED chelator
([68Ga]PSMA-11, also known as [68Ga]PSMA-HBED-CC)
[13]. A recent meta-analysis published by Perera et al.
showed on a per lymph node analysis a high sensitivity of
75% and a 99% specificity [14] for [68Ga]PSMA-11 PET/
CT. Because of several advantages of the positron emitter
18F, 18F-labelled PSMA ligands ([18F]PSMA-1007,
[18F]DCFPYL) were used more and more for imaging in-
stead of 68Ga-labelled PSMA ligands [15, 16].
If PET/CT indicates “regional pelvic LNM” as the only
finding at clinical recurrence, surgical removal (i.e. “sal-
vage lymphadenectomy” (salvage-LA [17, 18]) of the
lymphatic tissue or targeted RT may be suggested in pa-
tients in good general condition [6, 18, 19]. These “active
approaches” are offered in order to delay systemic ther-
apies [3, 18, 20, 21]. Against the background of the
guidelines (e.g. European guidelines), salvage LND or
target RT should be considered to be experimental and
individual therapeutic approaches [3].
Locating suspected recurrent LNM during surgery is
often very challenging in case of small LNM and re-
duced accessibility to the LNM (e.g. because of atypical
location of LNM and tissue adhesions) [11]. Positron-
emitting tracers are highly suitable for PET imaging but
inappropriate for locating LNM during surgery because
the γ-energy of their annihilation photons is too high for
standard γ-probe devices. More appropriate for tracking
of radioactively tagged LNM during surgery are γ-
emitting tracers such as [111In]PSMA-I&T [22],
[99mTc]PMSA-I&S [23] or [111In]PSMA-DKFZ-617 [24]
which also allow imaging as the PET tracers but with re-
duced spatial resolution, sensitivity and contrast due to
the single photon emission computer tomography
(SPECT) imaging technique [11, 25–27]. Without any
doubt, there is a clear need to improve the identification
of LNM during difficult surgery, regardless if at primary
LA or at salvage LA [6, 11, 26, 28].
111In-labelled PSMA ligands were successfully intro-
duced recently for imaging as well as for intraopera-
tive use (radio-guided surgery (RGS)) [11, 21, 28–30].
After intravenous tracer injection prior to surgery,
suspected LNM could be identified during surgery by
applying a γ-probe with acoustic feedback. Accord-
ingly, the surgeon is able to conduct in situ and ex
situ measurement of suspected regions for LNM and
resected tissue samples.
The recent development in the field of RGS for nodal
recurrent PCa relapse is the application of 99mTc-la-
belled PSMA by Maurer et al. [25]. Based on the investi-
gation of 31 patients with nodal PCa recurrence
undergoing a salvage LND with the use of a γ-probe,
they could show (specimen based) an impressive sensi-
tivity of 83.6%, a specificity of 100% and an accuracy of
93% [25]. However, the identification of an optimal
tracer for RGS salvage LND is still under investigation
[26], and RGS is applied differently at the institutions of-
fering this kind of experimental approach [11, 26, 31].
Recently, our group investigated the tracer uptake
of [111In]PSMA-617 at a “single LN level” (manual
separation of the resected tissue samples into single
LN and LNM) in six patients demonstrating an excel-
lent performance for the distinction between affected
and non-affected LN (92.1% sensitivity, 98.9% specifi-
city) [11].
The aim of this report was to evaluate the perform-
ance of the [111In]PSMA-617 on “region level” for a lar-
ger number of cases by analysing resected tissue samples
from LA in order to distinguish between affected
(mainly LNM) and non-affected tissue in men with sus-
pected LNM on a PSMA-PET/CT using [68Ga]PSMA-
11. Counts per second measured by γ-probe (ex situ),
tissue sample tracer uptake measured with a germanium
detector (ex situ) and PET/CT findings were correlated
with histopathology. Based on the clinical requirement
for high specificity (e.g. > 95%), the thresholds for both
ex situ measurements were selected accordingly.
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Material and methods
Patients
Between May 2015 and October 2016, 23 patients with
the suspicion of exclusive LNM (without detectable bone
or visceral metastases) on PSMA-PET/CT underwent
LA guided by [111In]PSMA-617. Two of 23 patients
underwent extended LA in the primary setting (radical
prostatectomy), and 21/23 patients at the stage of
biochemical recurrence (PSA > 0.2 ng/ml after radical
prostatectomy) underwent salvage LA on a compassion-
ate use basis. The local ethics committee approved this
retrospective data analysis (no. 562/15). Informed con-
sent was obtained from each subject, and all procedures
were performed in accordance with the Helsinki Declar-
ation. After surgery, the patients were treated according
to the German S3 guidelines for treatment of PCa [2]; in
case of PCa progression, a restaging by imaging (prefera-
ble PSMA-PET/CT) was done.
Tissue samples from eight subregions were excluded
from the contingency analysis because a follow-up
PSMA-PET/CT clearly showed the persistence or pro-
gression of the PET-positive lesion(s) and thereby that
the LN(s) had obviously not been removed during
surgery (e.g. difficulty in surgical access or because of
inappropriate high surgical risks). Consistently, tissue
samples from these “true-PET-positive” subregions have
been therefore excluded from the analysis due to
absence of tumour tissue and correspondingly negative
γ-probe and germanium detector measurements.
Mean PSA follow-up was 31.2 ± SD 12.8 months;
median follow-up at latest restaging (imaging) was 25.7
± SD 16.3 months.
PSMA-HBED-CC-PET/CT and imaging analysis
[68Ga]PSMA-11 was conducted as described by Jilg et al.
[6, 11]. Imaging was done 1 h after injection of averaged
202 ± SD 25 MBq [68Ga]PSMA-11. Contrast-enhanced
diagnostic CT was used for anatomical correlation and
PET attenuation correction. Two experienced nuclear
medicine physicians evaluated all the PET/CT studies in
consensus by side-by-side review of the co-registered
PET and CT datasets using predefined PET window set-
tings (inverted grey scale, SUV range 0 to 5 g/ml). All
patients showed increased focal [68Ga]PSMA-11 uptake
in at least one pelvic and retroperitoneal region. A
PSMA-positive lesion was defined as focal tracer accu-
mulation at least two times greater than normal or
physiological local background activity.
Synthesis of 111indium-labelled PSMA
The DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tet-
raacetic acid)-conjugated PSMA-617 was labelled with
111InCl3 under Good Laboratory Practice within 30 min
at 95 °C in ammonium acetate buffer. PSMA-617 was
obtained from ABX advanced biochemical compounds
(Radeberg, Germany). The radiotracer solution was
prepared by dilution with 0.9% NaCl. The radiochemical
purity of the final product was ≥ 97% and the decay-
corrected yield was > 95%. On average 44 ± 10 h prior
to surgery, patients received an intravenous application
of [111In]PSMA-617 (mean 110 ± 14 MBq). A PSMA
single-photon emission CT (SPECT/CT) was conducted
with a mean of 23.4 ± 1.2 h prior to surgery to ensure
sufficient tracer accumulation in the suspected tumour
lesions.
Procedure at lymphadenectomy
The extent of LA was determined first by the aim to
adhere to a template LA according to the presence of
PET-positive lesions: in the case of a pelvic PET-positive
lesion(s), a bilateral pelvic LA was intended whenever
possible (conducted in 19/23 men). In the case of an
additional PET-positive lesion in the retroperitoneum, a
retroperitoneal LA was conducted (Table 1). Subregions
for a template pelvic bilateral LA were as follows: com-
mon iliac vessels, external iliac vessels, obturator vessels,
internal iliac vessels (presacral region). Subregions for a
template retroperitoneal LA were as follows: aortic bifur-
cation, aortal, caval, as described by Jilg et al. [6]. When-
ever permitted by the intraoperative circumstances
(deviation from the template, e.g. caused by surgical dif-
ficulties), we adhered to this template. Nodal fibrofatty
tissue from each subregion was collected separately at
surgery [6]. Furthermore, the knowledge of the PET/CT
results (location of suspected LNM) also had an impact
on the extent of LA in the corresponding subregion(s).
Finally, the number of counts from the γ-probe used
intraoperatively (ex situ measurement) gave the surgeon
feedback if the suspected tumour tissue was resected or
if the LA in this subregion had to be continued which
ultimately increased the intensity of LA in this
subregion.
Analysis with γ-probe
After removal of the 275 specimens, counts per second
(CPS) were registered with a γ-probe (Neoprobe® GDS
ex situ). To generate comparable data between patients,
CPS were normalised (CPSnorm) to the injected activity
per kilogram lean body mass and decay-corrected to the
time of surgery (48 h representing the median time after
injection of [111In]PSMA-617 and the median time of ex
situ γ-probe measurements) in the patient group.
Analysis with germanium detector
All samples were weighed. Tissue sample activity
measurements were done with a high-purity germanium
detector (Canberra Inc., model GX2018-CP5+, calibrated
with a multi-isotope reference source, type VZ-2139/
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Table 1 Patient characteristics, history of prostate cancer and outcome from lymphadenectomies from 23 patients undergoing
lymphadenectomy
Parameters Values
iPSA at primary therapy (ng/ml)
Mean ± SD/median/range 10.79 ± 7.5/8.8/3.37–37.0
Primary therapy, n
Radical prostatectomy 21/23 (91.3%)
Radiotherapy 2/23 (8.7%)
Gleason score, n
7a 4 (17%)
7b 7 (31%)
8 5 (22%)
9 7 (30%)
111In-PSMA-guided LA overall, n
Primary 2/23 (8.7%)
Salvage lymph node dissection 21/23 (91.3%)
Age at lymphadenectomy (years)
Mean ± SD/median/range 67.5 ± 6.6/67/52–78
PSA at 111In-PSMA-guided LA (ng/ml)
Mean ± SD/median/range 7.9 ± 12.9/1.8/0.03–56.2
Time between PET/CT and 111In-PSMA-guided LA (months)
Mean ± SD/median/range 3.2 ± 1.6/3.0/1.0–8.0
Time between primary therapy and 111In-PSMA-guided LA (years) (n = 21)
Mean ± SD/median/range 4.9 ± 3.7/4.4/1.5–13.7
Histological outcome for 23 patients, n
LA with positive histology 21/23 (91.3%)
LA with negative histology 2/23 (8.7%)
Topography of 111In-PSMA-guided LA in 23 patients, n
Pelvic right and left 13/23 (57%)
Pelvic left only 2/23 (9%)
Pelvic right only 1/23 (4%)
Pelvic right and left and retroperitoneal 7/23 (30%)
Topography of subregions with confirmed PCa, n
Pelvic left, n 38/275 (37%)
Pelvic right, n 41/275 (40%)
Retroperitoneal 24/275 (23%)
Histological outcome for 275 subregions with 275 samples, n
Subregions/samples with LNM 104/275 (37.5%)
Subregions/samples without LNM 171/275 (62.5%)
Subregions/samples with additional non-nodal PCa-tissue 7/104 (5.8%)
Number of LN removed (n)
Overall 864
Per patient (mean ± SD/median/range) 37.6 ± 17.2/38.0/2.0–82.0
Number of LNM removed (n)
Overall 197
Per patient (mean ± SD/median/range) 8.6 ± 14.9/4.0/0.0–71.0
LNM fraction per patient (LNM×100/LN = %)
Mean ± SD/median/range 20.9 ± 24.4/12.5/0.0–87.1
LNM lymph node metastases, LN lymph node, PSA prostate-specific antigen, LA lymphadenectomy
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NG3 from Eckert&Ziegler Nuclitec’s DKD-accredited
measurement laboratory in Germany, and cross-
calibrated for tissue sample geometry). Tracer uptake
was calculated as percent injected activity per kilogram
lean body mass, corrected for decay:
%IAlbm ¼ tissue sample activity Bq½   100
injected activity Bq½ ∙2−Δt=T1=2 =lean body mass kg½ 
with Δt and T1/2 being the delay between patient injec-
tion and sample measurement and the half-life of 111In
(2.81 days [32]), respectively. Lean body mass was calcu-
lated according to Janmahasatian et al. [33] and used for
normalisation instead of body weight, since fat tissue
does not participate in normal tracer distribution.
Histopathological analysis
All resected LNs (i.e. the entire LN in case of small LNs,
one central slice in case of LNs > 4 mm) were fixed with
formalin and embedded in paraffin. The pathologist was
not aware of the PET findings and did not know the
clinical report of the tissue from the surgeon. Histopath-
ologic evaluation was performed by one pathologist on
haematoxylin and eosin (H&E)-stained tissue slides.
Statistical analysis
Analysis of findings (positive, negative) of PET/CT, γ-
probe and germanium detector in a contingency table
was done for 267 of 275 subregions; 8 subregions were
excluded from the contingency analysis because a
follow-up PSMA-PET/CT showed the persistence or
progression of the PET-positive lesion(s) indicating that
the LN(s) had not been removed during surgery. De-
scriptive statistics were done by calculating means,
standard deviations (SD), medians and ranges. From all
resected tissue samples, we had the information of the
γ-probe and germanium detector results as well as the
histopathological outcome. Based on these data, we
performed a ROC curve analysis (receiver operating
characteristic curve). Continuous variables were com-
pared with a two-sided unpaired Mann-Whitney test.
Diagnostic accuracy of γ-probe (CPSnorm), germanium
detector tracer-uptake measurement (%IAlbm) and PET/
CT was described by a contingency table. We used
Prism 6 GraphPad.
Results
Clinical data summarising the stage of PCa and LAs of
the 23 patients are shown in Table 1. In the majority
(21/23), LA were done in the setting of salvage LA
because of suspected LNM on a PSMA-PET/CT at the
stage of biochemical recurrence. Mean PSA level at
surgery was 7.9 ng/ml. For 21 of 23 patients, histo-
logical outcome confirmed the presence of PCa in the
removed tissue samples; in the remaining 2/23 patients,
it was not possible to remove the PET-positive lesions.
By PSMA-PET/CT follow-up, the PET-positive lesions
in those two patients showed a clear progression or
persistence of the metastases. Complications from
surgery, analysed according to Clavien-Dindo [34], are
shown in Table 2.
Figure 1a–f shows two representative PSMA-PET/CT
and SPECT/CT with an LNM in the left parailiacal re-
gion (patient no. 1) and in the right parailiacal region
(patient no. 2). A median of 38 LN had been removed
during LA per patient, of which a median of 4.0 turned
out to be metastases. Overall, a high number of subre-
gions (n = 275) underwent LA, and a high number of
LN (n = 864) had been removed (Table 1).
The workflow of the sample processing is shown in
Fig. 2. From 275 subregions, 275 tissue samples, consist-
ing of LN, LNM and fibrofatty tissue, were removed
separately and measured with a γ-probe and in a germa-
nium detector ex situ. The origin of 275 tissue samples
is shown in Table 1.
Figure 3 shows representative nodal fibrofatty tissue
samples from one subregion (a, b), γ-probe measure-
ments (c) and sample vessels for the tracer uptake
measurements (d).
Histopathological analysis of the 275 tissue samples
yielded 171 samples free of tumour and 104 samples
with tumour (mainly LNM).
Results of CPSnorm and %IAlbm tracer uptake from
tumour-containing (n = 104) and tumour-free (n = 171)
samples were significantly different (both p < 0.0001)
which is shown in Table 3. Samples without tumour had
a median of 3.0 CPSnorm and 0.03 %IAlbm compared with
a median of 33.5 CPSnorm and 0.71 %IAlbm measured
from samples with tumour. This high degree of separ-
ation by γ-probe and germanium detector measurements
is also shown in Fig. 4 c and d by comparing the me-
dians ± range of CPSnorm and %IAlbm in scatter plots.
Each corresponding value of CPSnorm and %IAlbm from
275 tissue samples is displayed in Fig. 4 a and b in a
waterfall plot. Red lines highlight the cut-off(s) for both
measurements.
Based on the clinical requirement of high specificity (>
95%), a threshold of > 23 CPSnorm and > 0.27 %IAlbm
was determined to reduce the risk of false-positive
samples. For a cut-off of > 23 CPSnorm, we determined a
sensitivity of 62.1% and specificity of 96.3%. It has to be
mentioned that for patient-individual γ-probe CPS
measurements during surgery, the threshold of 23
CPSnorm has to be multiplied by the injected activity per
kilogram lean body mass. After applying the cut-off of >
0.27 %IAlbm, we calculated a sensitivity of 71.2% and a
specificity of 96.9% comparable to PET/CT (sensitivity
of 79.8% and specificity of 96.9%) (Table 4).
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Figure 5 shows the intersections of true- and false-
positive as well as true- and false-negative subregions
from PSMA-PET/CT findings, γ-probe and germanium
detector measurements with Venn diagrams.
One hundred forty-seven of 171 (85.9%) specimens
free of cancer were correctly identified as true negative
by all three modalities (Fig. 5c). In contrast, only 54/104
(51.9%) of the specimens with cancer had been identified
correctly as true positive by all three modalities (Fig. 5a).
Additional file 1: Table S1 shows data about the
clinical course after surgery regarding PSA values and
follow-up imaging by mainly PSMA-PET/CT. Most (14/
23) of the patients developed clinical progression after
salvage LND.
Discussion
By targeting PSMA on cancer cells with 111In- or 99mTc-
labelled PSMA ligands, RGS was successfully introduced
for intraoperative use with a γ-probe and acoustic
feedback by Maurer et al. [11, 21, 25, 26, 28]. As those
previous works analysed so-called “mixed-tissue sam-
ples” containing LN, LNM and fibrofatty tissue, a more
specific investigation of the [111In]PSMA-617 tracer up-
take at a single LN level was done by our group [11].
Based on 275 tumour-free single LNs and 35 single
LNMs, after manual separation out of resected tissue
samples, a sensitivity of 92.1% and specificity of 98.9%
were reported, indicating a convincing tumour-specific
uptake in PCa lesions [11].
Rauscher et al. reported on 31 men undergoing RGS
with 111In-labelled PSMA ligand because of nodal PCa
relapse. One hundred forty-five mixed-tissue samples
were resected (51 tumour bearing) and measured ex situ
with a γ-probe. Sensitivity was 92.3%; specificity was
93.5% [29]. RGS described by Maurer et al. and Rauscher
et al. was predominantly restricted to PET-positive re-
gions only and their immediate vicinity [28, 29].
A unique feature in our study is the measurement of
tracer uptake of the resected tissue samples directly after
surgery in a germanium detector, which can be consid-
ered as a precise verification of γ-probe measurement.
Such an effort is not a part of clinical routine and was
done only for the cohort presented here. Due to tracer
availability, isotope costs and radiation protection issues,
99mTc-labelled PSMA is currently used for RGS, and our
cohort provides uniform data from the relatively limited
experience with RGS 111In-labelled PSMA.
Although in situ γ-probe measurement was done in
this study, a usual standard γ-probe with “pencil-geom-
etry” is not well engineered yet in terms of size and
angle for the application in a narrow pre-treated pelvic
region.
During practice in salvage LND with a γ-probe, it
turned out that sufficient contact between the γ-probe
and the tissue region (ideally 90° corresponding to the
collimator angle) in situ was not always possible because
of restricted spatial conditions. Therefore, we focused on
the ex situ measurements of the removed tissue samples
with the γ-probe (CPSnorm) and the subsequent tracer
Fig. 1 a, d Transversal CT and b, e PET of a PSMA-PET/CT with from two different representative patients no. 1 and no. 2 with suspected lymph
node metastases (LNM) prior to lymphadenectomy. c, f Preoperative (48 h preoperatively) transversal SPECT of the same patient. Suspected LNMs
are indicated by a red arrow
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uptake measurements with a germanium detector
(%IAlbm).
Usually, tissue samples from one subregion consist of
LN, LNM, fat, small vessels and fibrofatty tissue. Because
of unspecific tracer uptake within such a tissue mix,
false-positive signals might arise at γ-probe and germa-
nium detector measurements. On the other hand, a spe-
cific tracer signal in tumour tissue might be weakened
due to attenuation in large mixed-tissue samples enclos-
ing fibrofatty tissue, fat or small vessels, leading to false-
negative results, especially in the case of a very small
amount of tumour tissue.
Because of the clinical need for a low number of
false-positive results (to prevent the surgeon from mis-
interpretation and early termination of the LA),
expressed by a high specificity (e.g. > 95%), we chose
Fig. 2 Workflow and tissue sample processing from 23 lymphadenectomies after surgery with [111In]PSMA-617. Resected tissue specimens
(consisting out of LN, LNM and fibrofatty tissue) from a total of 275 subregions were analysed with a γ-probe at surgery followed by
histopathological analysis. Tracer uptake in tissue samples was analysed with a germanium detector. The asterisk symbol indicates that 8 of 275
subregions were excluded from the analysis because a follow-up PSMA-PET/CT showed the persistence or progression of the PET-positive
lesion(s) indicating that the LN(s) had not been removed during surgery
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the threshold for both measurements appropriately.
Consequently, both measurements yield a relatively low
sensitivity (Table 4).
Figure 5a shows an overlap of 51.9% (54/104) for true-
positive subregions for all three methods in the Venn
diagram. With 83/104 true-positive-rated subregions, the
detection rate of PET/CT seems to be excellent
compared with the germanium detector (75/104) and γ-
probe (64/104) measurement. This might result from the
fact that the resected mixed-tissue samples (LN, fat,
fibrofatty tissue) were larger when undergoing ex situ
measurements by germanium detector and γ-probe than
the spatial resolution of PET/CT. Under these circum-
stances, PET/CT is able to discriminate between lesions
with specific PSMA uptake and the surrounding tissue
with lower, unspecific uptake than the ex situ
measurements.
Interestingly, there was no overlap for false-positive
subregions between PET/CT, germanium detector and
γ-probe (Fig. 5b). There is no obvious reason for this
result but the methodology of the three measurements
is very different and the uptake times between
[68Ga]PSMA-11 imaging and [111In]PSMA-617 mea-
surements differ too. While PSMA-PET/CT was re-
corded 1 h post injection, it might have a higher uptake
in regions with higher perfusion. [111In]PSMA-617 was
measured 48 h post injection with nearly complete
tracer wash-out but remaining unspecific tracer accu-
mulation [27].
Germanium detector measurements are very accurate
in determining activity in specified sample geometry. For
larger samples containing mixed-tissue compositions
with fat, fibrofatty tissue, small vessels and LN, the inter-
pretation of the results can only be done as an averaged
value for the whole sample. In addition to a generally
possible lack of PSMA expression, false-negative results
might be caused by very low tumour load (e.g. very small
LN) and attenuation of tracer signal due to enclosed tis-
sue in the sample (Fig. 5d). Measurements of mixed-
tissue samples with a germanium detector as presented
in this study are therefore not comparable to the known
excellent sensitivity (92.3%) and specificity (93.5%) from
Fig. 3 a Representative resected tissue sample from a subregion consisting of lymph nodes and fibrofatty tissue. b, c γ-probe measurement
(counts per second) from a tissue sample. d Representative collection of 6 tissue samples from 6 subregions for analysis of tracer uptake in the
germanium detector
Table 2 Complications arising from 23 lymphadenectomies
Complications according to Clavien-Dindo Grade Overall, n (%)
Lymphorrhea I 3/23 (13.04%)
Transient weakness of hip flexor I 1/23 (4.35%)
Wound dehiscence I 1/23 (4.35%)
Wound infection treated with antibiotics II 1/23 (4.35%)
Lymphorrhea requiring drainage, secondary IIIa 2/23 (8.7%)
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the analysis of “single lymph nodes” in such a device
[11]. The reasons are the methodological limitations
discussed.
As shown by our group previously [35], the LN detec-
tion rate for PSMA-PET/CT was reduced to 50% for
tumour deposits < 2.2 mm in LNM; consequently, one
could assume that the false-negative subregions might
harbour very small amounts of tumour (only detectable
at histopathology) or tumour cells were negative for
PSMA.
However, currently, we could not identify a common
pattern of subregions rated as false negative or false
positive on PET/CT, γ-probe or at germanium detector
analysis. Neither the clinical data from patients provid-
ing those subregions nor the locations of the subregions
were apparently different from the rest.
The majority of our small cohort developed clinical re-
currence (14/23) (follow-up was 31.2 ± SD 12.8 months).
From our experience [17] and the latest literature (meta-
analysis of 27 series), it is known that the 2- and 5-year
biochemical progression-free survival rates range from
23 to 64% and from 6 to 31%, respectively; the 5-year
overall survival is approximately 84% [18, 36]. By rough
estimation, our cohort has an outcome which is not
better than that of patients treated with conventional
salvage LND.
Fig. 4 a Waterfall plot of the CPSnorm [CPS/(MBq/kg)] and b tracer uptake [%IAIbm] of tumour-free samples and tumour-containing samples
illustrating the power of discrimination of [111In]PSMA-617. CPSnorm (c) and %IAIbm (d) from samples with and without tumour is shown in scatter
plots; horizontal black lines represent the medians ± range. ***p ≤ 0.001
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Currently, salvage LND for patients with nodal re-
current LNM or nodal high-volume LNM at primary
therapy (rad. PE) at our centre is done guided by
99mTc-labelled PSMA with ex situ γ-probe measure-
ment but without germanium detector measurement
in the laboratory, similar to the approach of Maurer
et al. [25].
The clinical benefit of RGS salvage LND compared
with conventional salvage LND is still unclear. Knipper
et al. made the first approach of comparing conventional
salvage LND (n = 29) versus salvage LND with radio-
guided assistance (n = 13) [31]. After a short follow-up
(6 weeks), they were able to show a better PSA decline
in general for the RGS salvage LND compared with
Fig. 5 a–d Venn diagrams illustrating the intersections between the results of PSMA-PET/CT, tracer uptake determined with the germanium
detector and ex situ γ-probe measurements. Intersections for a true-positive, b false-negative, c true-negative and d false-positive subregions in
104 subregions with histologically proven metastases and 171 subregions free of metastases
Table 3 γ-probe and germanium detector measurements from 275 tissue samples of 275 subregions
Samples with tumour (n = 104) Samples without tumour (n = 171) Mann-Whitney test, p value
Germanium detector [% IAlbm]*
Median/mean ± SD/range 0.71/2.6 ± 5.4/0.008–36.33 0.03/0.07 ± 0.17/0–0.817 < 0.0001
γ-probe [CPSnorm]†
Median/mean ± SD/range 33.5/49.0 ± 49.5/0–213.0 3.0/5.9 ± 11.2/0–118.0 < 0.0001
*Percent injected activity per kilogram lean body mass
†Counts per second decay corrected to 48 h and normalised to injected activity megabecquerel per kilogram lean body mass
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conventional salvage LND [31]. It can be assumed that
the trend towards assisted or guided surgery such as
RGS will continue, bearing in mind that more informa-
tion before surgery and during surgery will potentially
achieve better results.
Bimodal-labelled anti-PSMA antibodies such as 68Ga-
Glu-urea-Lys-HBED-CC-IRDye800CW/68Ga-Glu-urea-
Lys-(HE)3-HBED-CC-IRDye800CW enabling the track-
ing of tumour tissue via fluorescence and γ-emission
during surgery are under investigation [37, 38]. By using
fluorescence imaging as a tool to separate healthy LN
tissue from LNM during robot-assisted laparoscopy,
bimodal-labelled anti-PSMA antibodies are of great
interest [39].
Limitations
Although the number of patients (n = 23) seems to be
relatively low, the actual sample size (n = 864 LN from
275 subregions) was very high. Even if the majority of
the patients were at high risk for PCa, heterogeneity was
present (PSA level, Gleason score, different kind of
previous therapies).
Generally, there is a selection bias because only pa-
tients with suspected LNM on PSMA-PET/CT and
therefore known PSMA-positive lesions were included in
this study. Furthermore, ideally in all patients, an identi-
cal bilateral template LA should have been performed
which is hard to realise for all patients for different rea-
sons (e.g. surgical access). However in our cohort, only
4/23 (13%) received a unilateral lymphadenectomy (at
the site of a PET-positive lesion); this might weaken the
reliability of sensitivity and specificity in our calculation.
However, our high number of analysed “subregions”
(small anatomical regions) (n = 275) and our high
number of removed LN (n = 864) might provide better
diagnostic information than a simple summary in, e.g.
left- or right-sided lymph nodes. In summary, 179 PET-
negative and 88 PET-positive subregions underwent an
LA, which allows, in our view, specificity and sensitivity
to be calculated.
Conclusions
At a region-based analysis, the results for tracer uptake
measurements (γ-probe, germanium detector) were
significantly different between tumour-affected and
tumour-free samples. In the clinical setting with the
need for high specificity (> 95%) and a corresponding
chosen threshold for γ-probe measurement (confirmed
by precise germanium detector measurements), the use
of [111In]PSMA-617 at LA is feasible for the distinction
between affected and unaffected tissue samples and valu-
able for ex situ tumour verification during surgery.
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